{"id":2224,"date":"2023-06-22T16:49:55","date_gmt":"2023-06-22T16:49:55","guid":{"rendered":"https:\/\/avaeh.org\/web_nueva_2021\/?p=2224"},"modified":"2023-06-22T16:52:52","modified_gmt":"2023-06-22T16:52:52","slug":"uniqure-anuncia-actualizacion-sobre-el-ensayo-clinico-de-fase-i-ii-en-ee-uu-de-la-terapia-genica-amt-130-para-el-tratamiento-de-la-enfermedad-de-huntington","status":"publish","type":"post","link":"https:\/\/avaeh.org\/web_nueva_2021\/2023\/06\/22\/uniqure-anuncia-actualizacion-sobre-el-ensayo-clinico-de-fase-i-ii-en-ee-uu-de-la-terapia-genica-amt-130-para-el-tratamiento-de-la-enfermedad-de-huntington\/","title":{"rendered":"uniQure anuncia actualizaci\u00f3n sobre el ensayo cl\u00ednico de fase I\/II en EE. UU. de la terapia g\u00e9nica AMT-130 para el tratamiento de la enfermedad de Huntington"},"content":{"rendered":"\n

\u00abA pesar del peque\u00f1o n\u00famero de pacientes, me alienta ver que los pacientes tratados con cualquiera de las dosis de AMT-130 parecen tener una funci\u00f3n conservada en gran medida y tienen una tendencia favorable al curso natural de la enfermedad hasta los 24 meses. Estos resultados provisionales brindan una esperanza temprana para los pacientes que padecen esta enfermedad devastadora\u00bb Sarah Tabrizi, MD, FRCP, Ph. .D., profesor de neurolog\u00eda cl\u00ednica, director del Centro de Enfermedades de Huntington del University College London (UCL) y jefa conjunta del departamento de enfermedades neurodegenerativas de la UCL.<\/p>\n\n\n\n

ART\u00cdCULO COMPLETO EN WEB<\/a><\/p>\n\n\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

\u00abA pesar del peque\u00f1o n\u00famero de pacientes, me alienta ver que los pacientes tratados con cualquiera de las dosis de AMT-130 parecen tener una funci\u00f3n conservada en gran medida y tienen una tendencia favorable al curso natural de la enfermedad hasta los 24 meses. Estos resultados provisionales brindan una esperanza temprana […]<\/p>\n","protected":false},"author":1,"featured_media":2225,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[623,625,7,6,4,9,624,621,5,58,8,323,622],"class_list":["post-2224","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categoria","tag-amt-130-2","tag-amt-130-huntington","tag-asociacion-valenciana-de-enfermedad-de-huntington","tag-avaeh","tag-enfermedad-de-huntington","tag-enfermedades-raras","tag-ensayo-amt-130","tag-huntington-investigacion","tag-huntingtons-disease","tag-neurodegenerativa","tag-rare-diseases","tag-uniqure","tag-uniqure-huntington"],"_links":{"self":[{"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/posts\/2224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/comments?post=2224"}],"version-history":[{"count":2,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/posts\/2224\/revisions"}],"predecessor-version":[{"id":2227,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/posts\/2224\/revisions\/2227"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/media\/2225"}],"wp:attachment":[{"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/media?parent=2224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/categories?post=2224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/tags?post=2224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}